Literature DB >> 16088436

Pathogenesis and treatment of acute exacerbations of chronic obstructive pulmonary disease.

Sanjay Sethi1.   

Abstract

Once thought to be a mere nuisance, exacerbations are now recognized as a major contributor to the morbidity and mortality associated with chronic obstructive pulmonary disease. This recognition has led to research using new investigative tools that has substantially enhanced our understanding of the pathogenesis of exacerbations. Several overlapping etiologies can precipitate the symptom complex of an exacerbation. Treatment of exacerbations requires the use of several therapeutic modalities with the goal of restoring the patient to baseline. Results of recent clinical trials and observational studies have allowed a refinement of the approach to treatment of exacerbations. These include a rational, stratified approach to the use of antibiotics and several trials substantiating the use of systemic corticosteroids. Relapse or failure rates of 20 to 33% have been described in the treatment of acute exacerbation, with these treatment failures contributing substantially to the costs associated with exacerbations. Improved treatment based on enhanced understanding and good clinical evidence should lead to better outcomes in this common clinical entity.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16088436     DOI: 10.1055/s-2005-869538

Source DB:  PubMed          Journal:  Semin Respir Crit Care Med        ISSN: 1069-3424            Impact factor:   3.119


  5 in total

Review 1.  Pathogenesis of inflammation and repair in advanced COPD.

Authors:  William D Cornwell; Victor Kim; Changcheng Song; Thomas J Rogers
Journal:  Semin Respir Crit Care Med       Date:  2010-05-21       Impact factor: 3.119

2.  Cefditoren versus levofloxacin in patients with exacerbations of chronic bronchitis: serum inflammatory biomarkers, clinical efficacy, and microbiological eradication.

Authors:  Francesco Blasi; Paolo Tarsia; Marco Mantero; Letizia C Morlacchi; Federico Piffer
Journal:  Ther Clin Risk Manag       Date:  2013-02-12       Impact factor: 2.423

3.  Alterations in the expression of the NF-κB family member RelB as a novel marker of cardiovascular outcomes during acute exacerbations of chronic obstructive pulmonary disease.

Authors:  Laura Labonté; Patrick Coulombe; Michela Zago; Jean Bourbeau; Carolyn J Baglole
Journal:  PLoS One       Date:  2014-11-19       Impact factor: 3.240

4.  Soluble triggering receptor expressed on myeloid cells 1 is released in patients with stable chronic obstructive pulmonary disease.

Authors:  Markus P Radsak; Christian Taube; Philipp Haselmayer; Stefan Tenzer; Helmut R Salih; Rainer Wiewrodt; Roland Buhl; Hansjörg Schild
Journal:  Clin Dev Immunol       Date:  2007

5.  The levels of serum pro-calcitonin and high-sensitivity C-reactive protein in the early diagnosis of chronic obstructive pulmonary disease during acute exacerbation.

Authors:  Dejie Gao; Xincan Chen; He Wu; Haidong Wei; Jinling Wu
Journal:  Exp Ther Med       Date:  2017-05-23       Impact factor: 2.447

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.